EJU Stock Chart & Stats
€1.89
€0.00(0.00%)
At close: 4:00 PM EDT
€1.89
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.89 - €1.89
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.51M
Enterprise Value-€1.07
Total Cash (Recent Filing)€5.03M
Total Debt (Recent Filing)€336.72K
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 13, 2026EPS Estimate
-3.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.17
Shares Outstanding2,633,560
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.51
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.73Price Target Upside-8.47% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-9.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Progression (Cohort Advancement)DSMB clearance for Cohort 2 and initiation of Cohort 3 materially de-risks the program on safety and shows the company can execute multicohort clinical work. Durable operational progress increases likelihood of subsequent trials and regulatory engagement, strengthening development credibility long-term.
Expense Discipline And Reduced Operating CostsSustained, sizable year-over-year expense reductions reflect active management of the cost base and improve structural burn dynamics. Lower fixed spending enhances runway flexibility, reduces dependence on urgent financing, and indicates stronger stewardship of capital—important for development-stage firms.
Device Compatibility With Simplified Blood PumpCompatibility with a simplified pump reduces infrastructure requirements and broadens potential treatment sites. This structural enabler can lower adoption friction, expand the addressable market beyond dialysis units, and improve commercial feasibility if clinical efficacy is demonstrated.
Bears Say
Constrained Liquidity Relative To Operating LossesReported cash balances plus recent ATM proceeds appear insufficient to cover a full year of current operating losses, forcing reliance on incremental financings. This structural funding gap raises execution risk for clinical programs, increases dilution potential, and can constrain long-term strategy and trial pacing.
Persistent Operating Losses And Minimal RevenueOngoing multi-year losses with little-to-no recurring revenue erode shareholder equity and prevent internal funding of R&D. This structural lack of self-generated cash makes the business perpetually financing-dependent and heightens risk that development timelines and commercialization plans will be delayed without new capital.
Small, Non‑powered Study And Enrollment UncertaintyRelying on a small safety-focused trial limits near-term ability to demonstrate efficacy or obtain regulatory approvals. Enrollment attrition and small cohorts can delay definitive outcomes, require larger follow‑on trials, and materially extend the timeline and capital needed for commercialization—structural program risk.
Aethlon Medical News
EJU FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Aethlon Medical Inc lowest stock price was €1.89 and its highest was €1.89 in the past 12 months.
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is €1.51M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Aug 13, 2026 which is in 4 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Jun 10, 2026. The company reported €17.645 earnings per share for the quarter, beating the consensus estimate of -€9.366 by €27.011.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Overvalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -3.39.
How many shares outstanding does Aethlon Medical Inc have?
Aethlon Medical Inc has 2,633,560 shares outstanding.
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of €17.645 in its last earnings report, beating expectations of -€9.366. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in DE:EJU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
EJU Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated multiple operational and clinical progress points — completion of Cohort 2 with DSMB clearance, initiation of Cohort 3 with a successful first treatment, expansion of preclinical EV research into rheumatoid arthritis and chronic kidney disease, successful compatibility testing with a simplified blood pump, disciplined cost reductions (operating expenses down 21.9%), and an improved net loss (~46% reduction). However, material challenges remain: cash at fiscal year‑end was modest (~$5.0M) despite a subsequent ~$1.85M ATM raise, the company remains unprofitable (net loss $7.2M), the current oncology study is small and not powered for efficacy, and there is no near‑term commercial revenue or explicit commercialization timeline. Overall, operational and clinical execution trends are positive but balanced by funding and development‑stage risks.View all DE:EJU earnings summariesEJU Stock 12 Month Forecast
Average Price Target
€1.73
▼(-8.47% Downside)